An Introduction To Breast Cancer

Download as pdf or txt
Download as pdf or txt
You are on page 1of 22

Introduction to Breast Cancer

Anees B. Chagpar, MD, MSc, MA, MPH, MBA, FRCSC, FACS


@AneesChagpar
#breastcamooc

Associate Professor of Surgery, Yale School of Medicine


Director, The Breast Center – Smilow Cancer Hospital at Yale-New Haven
Assistant Director – Global Oncology, Yale Comprehensive Cancer Center
Program Director, Multidisciplinary Breast Fellowship, Yale University
What is Cancer?

• The disease caused by an


uncontrolled division of abnormal cells
in a part of the body

• A practice or phenomenon perceived


to be evil or destructive and hard to
contain or eradicate
Cancer in the US in 2015
Global Breast Cancer Incidence
Risk Factors

• Non-modifiable: • Modifiable:
– Gender – Exogenous hormones
– Age – Breast feeding
– Genetics – Alcohol
– Benign breast disease – Obesity
(e.g., atypical ductal – High dose radiation (?)
hyperplasia)
– Endogenous
hormones (?)
Calculate your risk

• http://www.cancer.gov/bcrisktool/Default.aspx
Breast Cancer Prevention

Anees B. Chagpar, MD, MSc, MA, MPH, MBA, FRCSC, FACS


@AneesChagpar
#breastcamooc

Associate Professor of Surgery, Yale School of Medicine


Director, The Breast Center – Smilow Cancer Hospital at Yale-New Haven
Assistant Director – Global Oncology, Yale Comprehensive Cancer Center
Program Director, Multidisciplinary Breast Fellowship, Yale University
Risk and Prevention

• Lung cancer
– Smoking → Don’t smoke!
• Cervical cancer
– HPV → HPV vaccine
• Breast cancer
– ???
Risk Factors

• Non-modifiable: • Modifiable:
– Gender – Exogenous hormones
– Age – Breast feeding
– Genetics – Alcohol
– Benign breast disease – Obesity
(e.g., atypical ductal – High dose radiation (?)
hyperplasia)
– Endogenous
hormones (?)
Risk Reducing Strategies

• Frequent surveillance 0%

• “Chemoprevention” ~50%
• Prophylactic oophorectomy

• Prophylactic mastectomy ~95%


Surveillance

• Self breast exam

• Clinical breast exam

• Mammography +/- ultrasound

• MRI
MRI

• BRCA 1 or 2 gene mutation carriers

• Family history of BRCA 1 or 2 gene mutation

• Lifetime risk of 20-25% or greater by


BRCAPRO or similar model
Chemoprevention

• Selective Estrogen Receptor Antagonists


– Tamoxifen
– Raloxifene

• Aromatase Inhibitors
– Exemestane

• Other agents?
Mechanism of Action

Ovary

Adrenal gland Aromatase in


Peripheral fat
Chemoprevention Trials
Tamoxifen
NSABP P-1 IBIS-1 Italian Royal
Marsden
Follow up 7 yrs 10 yrs 13 yrs 20 yrs
N 13,207 7154 5408 2471
RR (95% CI) 0.57 0.74 0.80 0.78
(0.46-0.70) (0.58-0.94) (0.56-1.15) (0.58-1.04)
Raloxifene Exemestane
CORE MORE RUTH MAP3
Follow up 8 yrs 4 yrs 7 yrs 3 yrs
N 7705 7682 10,101 4550
RR (95% CI) 0.33 0.28 0.56 0.35
(0.21-0.49) (0.17-0.46) (0.38-0.83) (0.18-0.70)
Eligibility/Side Effects

• Women > 35 years of age


• 5 year risk > 1.66 or history of LCIS
Tamoxifen Raloxifene Exemestane
Eligibility Premenopausal Post-menopausal
Side Effects
DVT/PE ↑↑ ↑ =
Endometrial cancer ↑↑ ↑ =
Cataracts ↑ = =
Fracture = ↓ =
Prophylactic Oopherectomy

• Reduce risk of breast cancer ~50%

• Reduce risk of ovarian cancer ~80%


Prophylactic Mastectomy

• Reduce breast cancer risk ~95%

• Newer surgical techniques

• Reconstruction

You might also like